Insights

Strong Industry Position WuXi Advanced Therapies is a prominent player in the rapidly growing cell and gene therapy market, providing comprehensive contract testing, development, and manufacturing services that cater to innovative biotech and pharmaceutical companies seeking reliable production partners.

Recent Strategic Expansion The company's recent acquisition by Altaris and planned merger with Minaris enhances its global manufacturing footprint and capabilities, creating opportunities to offer integrated, end-to-end solutions to clients expanding their cell and gene therapy portfolios.

Proven Innovation Track With technological advancements such as the launch of CAR-T therapy platforms and TESSA technology, WuXi ATU demonstrates its ability to develop cutting-edge therapies, making it attractive for clients seeking high-tech manufacturing partnerships.

Strong Collaborations Partnerships with leading biotech firms like Janssen and Wugen, combined with successful manufacturing agreements, indicate significant potential for new collaborations and service contracts with innovative therapy developers and biotechs.

Financial Growth Potential With annual revenues estimated between 100 to 250 million dollars and backing from a specialized healthcare investor like Altaris, WuXi Advanced Therapies is positioned for scaling its services, offering opportunities for sales of advanced testing, development, and manufacturing solutions to expanding clients.

WuXi Advanced Therapies Tech Stack

WuXi Advanced Therapies uses 8 technology products and services including Site Kit, Open Graph, jQuery, and more. Explore WuXi Advanced Therapies's tech stack below.

  • Site Kit
    Analytics
  • Open Graph
    Content Management System
  • jQuery
    Javascript Libraries
  • Prism
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • Swiper
    Javascript Libraries
  • ActiveCampaign
    Marketing Automation
  • Priority Hints
    Performance

Media & News

WuXi Advanced Therapies's Email Address Formats

WuXi Advanced Therapies uses at least 1 format(s):
WuXi Advanced Therapies Email FormatsExamplePercentage
First.Last@advancedtherapies.comJohn.Doe@advancedtherapies.com
84%
FLast@advancedtherapies.comJDoe@advancedtherapies.com
15%
First@advancedtherapies.comJohn@advancedtherapies.com
1%

Frequently Asked Questions

What is WuXi Advanced Therapies's official website and social media links?

Minus sign iconPlus sign icon
WuXi Advanced Therapies's official website is advancedtherapies.com and has social profiles on LinkedIn.

How much revenue does WuXi Advanced Therapies generate?

Minus sign iconPlus sign icon
As of December 2025, WuXi Advanced Therapies's annual revenue is estimated to be $500K.

What is WuXi Advanced Therapies's SIC code NAICS code?

Minus sign iconPlus sign icon
WuXi Advanced Therapies's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does WuXi Advanced Therapies have currently?

Minus sign iconPlus sign icon
As of December 2025, WuXi Advanced Therapies has approximately 501 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Operations Officer: R. F.Head Of Commercial,china: C. Y.Owner: J. D.. Explore WuXi Advanced Therapies's employee directory with LeadIQ.

What industry does WuXi Advanced Therapies belong to?

Minus sign iconPlus sign icon
WuXi Advanced Therapies operates in the Biotechnology Research industry.

What technology does WuXi Advanced Therapies use?

Minus sign iconPlus sign icon
WuXi Advanced Therapies's tech stack includes Site KitOpen GraphjQueryPrismjQuery MigrateSwiperActiveCampaignPriority Hints.

What is WuXi Advanced Therapies's email format?

Minus sign iconPlus sign icon
WuXi Advanced Therapies's email format typically follows the pattern of First.Last@advancedtherapies.com. Find more WuXi Advanced Therapies email formats with LeadIQ.

When was WuXi Advanced Therapies founded?

Minus sign iconPlus sign icon
WuXi Advanced Therapies was founded in 2004.

WuXi Advanced Therapies

Biotechnology ResearchPennsylvania, United States501-1000 Employees

Advanced Therapies is a cell therapy Contract Testing, Development and Manufacturing Organization (CTDMO.) We leverage our significant experience and proven track record in development and manufacturing, as well as expert testing services, to enable advanced therapies to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities and cost of high-touch, multi-vendor production models. 
On 7 March 2025, Advanced Therapies U.S. and our discovery arm, OXGENE (www.oxgene.com) were purchased by Altaris, an investment firm headquartered in the U.S. with an exclusive focus on the healthcare industry. With a 20+ year track record that includes 11 medical product CDMOs, Altaris is well-positioned to support Advanced Therapies over its next phase of growth. 
This transaction builds on Altaris’ strategic initiative for the cell and gene therapy market, which is focused on delivering life-changing therapies to patients at scale. As part of this strategy, Altaris acquired Minaris Regenerative Medicine (“Minaris”) from Resonac Holdings Corporation in January of this year. Minaris is a cell therapy contract development and manufacturing organization (CDMO) with operations in the United States, Germany and Japan.
Altaris intends to combine Advanced Therapies and Minaris into a single company, Minaris Advanced Therapies. The combined company’s extensive track record, breadth of capabilities and global manufacturing footprint will enhance our ability to service our customers, accelerate development timelines, reduce manufacturing costs, and improve patient access to life-saving treatments.
For now, Minaris and Advanced Therapies will continue to operate as two independent companies to ensure business continuity until the completion of certain separation milestones from their respective former parent companies. We expect them to be fully combined by the end of 2025.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2004
Employees
501-1000

Section iconFunding & Financials

  • $100M$250M

    WuXi Advanced Therapies's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $100M$250M

    WuXi Advanced Therapies's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.